about
Exercise therapy and other types of physical therapy for patients with neuromuscular diseases: a systematic reviewIntegrating ethics in health technology assessment: many ways to Rome.Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism.Living with myotonic dystrophy; what can be learned from couples? A qualitative study.The effectiveness and cost evaluation of pain exposure physical therapy and conventional therapy in patients with complex regional pain syndrome type 1. Rationale and design of a randomized controlled trial.Zinc supplementation inhibits complement activation in age-related macular degeneration.Ethical analysis in HTA of complex health interventionsEvidence for scaling up HIV treatment in sub-Saharan Africa: A call for incorporating health system constraints.AN INTEGRATED PERSPECTIVE ON THE ASSESSMENT OF TECHNOLOGIES: INTEGRATE-HTA.HEADROOM BEYOND THE QUALITY- ADJUSTED LIFE-YEAR: THE CASE OF COMPLEX PEDIATRIC NEUROLOGY.Towards a taxonomy of logic models in systematic reviews and health technology assessments: A priori, staged, and iterative approaches.The yield of diagnostic work-up of patients presenting with myalgia, exercise intolerance, or fatigue: A prospective observational study.Is the $1000 Genome as Near as We Think? A Cost Analysis of Next-Generation Sequencing.A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurologyThe diagnostic pathway in complex paediatric neurology: a cost analysis.Uncertainty on the effectiveness and safety of rivaroxaban in premenopausal women with atrial fibrillation: empirical evidence needed.Shared medical appointments improve QOL in neuromuscular patients: a randomized controlled trial.A multifaceted intervention to reduce guideline non-adherence among prescribing physicians in Dutch hospitals.Evidence-Informed Deliberative Processes – Early Dialogue, Broad Focus and Relevance: A Response to Recent Commentaries.The development of CHAMP: a checklist for the appraisal of moderators and predictors.TOWARD INTEGRATION IN THE CONTEXT OF HEALTH TECHNOLOGY ASSESSMENT: THE NEED FOR EVALUATIVE FRAMEWORKS.HEALTH TECHNOLOGY ASSESSMENT, DELIBERATIVE PROCESS, AND ETHICALLY CONTESTED ISSUES.TAKING PATIENT HETEROGENEITY AND PREFERENCES INTO ACCOUNT IN HEALTH TECHNOLOGY ASSESSMENTS.HOW TO AVOID GIVING THE RIGHT ANSWERS TO THE WRONG QUESTIONS: THE NEED FOR INTEGRATED ASSESSMENTS OF COMPLEX HEALTH TECHNOLOGIES.INTEGRATE-HTA: A LOW- AND MIDDLE-INCOME COUNTRY PERSPECTIVE.CHALLENGES IN CONTEMPORARY HEALTH TECHNOLOGY ASSESSMENT: A VIEW FROM THE OUTSIDE.Combining value of information analysis and ethical argumentation in decisions on participation of vulnerable patients in clinical research.Implementation of multidisciplinary advice to allied health care professionals regarding the management of their patients with neuromuscular diseases.ON IMPACT AND IMPACT FACTORS.Adrenal Vein Sampling Is the Preferred Method to Select Patients With Primary Aldosteronism for Adrenalectomy: Con Side of the Argument.Synthesis of evidence for reimbursement decisions: a Bayesian reanalysis.The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective.Structured methodology review identified seven (RETREAT) criteria for selecting qualitative evidence synthesis approachesA prediction model for primary aldosteronism when the salt loading test is inconclusivePrediction of clinically relevant adverse drug events in surgical patientsTO EVALUATE VERSUS TO KNOW THE VALUE OF EVERYTHINGEffect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 TrialsPrevalence and mutation spectrum of skeletal muscle channelopathies in the NetherlandsGenotype-Guided Thiopurine Dosing Does not Lead to Additional Costs in Patients With Inflammatory Bowel DiseaseOptimal search strategies for identifying moderators and predictors of treatment effects in PubMed
P50
Q28255099-797CCC2A-D795-4B08-B2D1-36BB4726F489Q30375523-CCF010F5-AC55-4DD4-A244-1DA6509E3B9AQ33498721-A981BC5A-6942-4DDF-810A-6F3D4545F4F3Q33959875-EF458BBD-2602-42E6-BAC1-331331BE7338Q34239287-E4AA6E50-F067-45EE-99C1-FD2BB2A6A695Q34506404-B2DFF6AC-425A-44CB-97C7-023338556F1FQ35966688-CC273E04-5EA2-4488-8A5B-C963E90AB064Q36286256-DBC2B9FA-3966-4E97-98D7-C2D0351D3891Q38653139-DE63EA63-E809-4E12-A990-CBE5E104ADECQ38677769-895E0765-66CB-400D-B23C-BFFFC28E6DFBQ38693481-77C901B4-A40C-42DA-B61A-58215BD3B9ECQ38771160-73F1C0E3-95BE-4B80-9E62-911A3BB9ABC5Q38803786-5181CC35-5882-46CA-ABF1-52A194C965B7Q38883296-C2B0CE99-7BF0-44DB-A993-D05CE083432BQ41554178-04148F03-BD9E-46B4-A034-58B723794604Q42377391-D69DE7AA-3933-4D23-9653-D9078F098F66Q42667160-13ED4D85-D549-4D75-9686-D26B62F2611DQ47110621-C084AA39-028A-41D9-9A5E-187FD5C8D136Q47121332-E9BFA9A6-9566-4889-945B-F3EF5BDCB749Q47265229-0CAE6CBE-28C4-44B7-9F2F-22A16833D876Q47278977-94071E41-D543-46E9-A000-A0DF68D12CB5Q47405653-390F73DB-7F1B-4A8F-A989-CDCE35FB3832Q47549181-756A782B-D376-486F-B8EE-838490E30830Q47602372-323746A4-D70E-4289-9DEF-DD21E225BDBFQ47627433-A047E928-31EA-4E6F-BE84-71CC3B92B2A3Q47830774-F17B2EA2-96D7-470B-AA1C-A961A42F6B36Q48103834-6B147BF6-1BEC-4165-A73F-C5627890619CQ48186954-342F662F-4242-4711-B791-BDE681F0A51EQ48506161-39C16ED7-B84B-4A21-8114-E6047D1D8E52Q49920748-634CA3EF-A8E8-4822-AFC4-3FC916376C17Q50179577-62DB5AD1-F40D-4A22-A4A7-C7519A7DEBD4Q54969941-7AFF7300-66AC-4261-9CB0-5A25B9B2C7A7Q57536277-E5165B41-9E74-40F6-A608-04B4472473B4Q57818899-FBCE129E-5D9D-4CD6-A002-BAF21B2CF0BBQ58715907-036ADEB9-41A7-4442-8C7F-745ECED36B74Q60464039-01BA01AA-67F0-487F-94D2-CC80D04CAF81Q64042128-E748C51E-5CDF-466A-995B-F6202AC8E001Q64045969-F5FE6A5B-68BD-4B13-A43A-E1D67D9E5BFBQ64083977-06925183-3106-474C-816D-B7A48BC17F95Q90159711-DD30D738-3D42-4A84-9512-C0781B542974
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Gert Jan van der Wilt
@ast
Gert Jan van der Wilt
@en
Gert Jan van der Wilt
@es
Gert Jan van der Wilt
@nl
type
label
Gert Jan van der Wilt
@ast
Gert Jan van der Wilt
@en
Gert Jan van der Wilt
@es
Gert Jan van der Wilt
@nl
prefLabel
Gert Jan van der Wilt
@ast
Gert Jan van der Wilt
@en
Gert Jan van der Wilt
@es
Gert Jan van der Wilt
@nl
P1053
H-8120-2014
P106
P31
P496
0000-0002-5856-762X